News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 145–180
- Matches
- 190
- Sources here
- 19
- Companies here
- 6
Search results
Stored financial headlines
Active search
190 matching headlines
Ticker or company: MACYMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte, Inc. (HUMA) saw its stock close at $0.67, a 2.22% increase, outperforming the S&P 500's daily gain, despite a 21.82% drop over the past month. Analysts project a significant increase in EPS and revenue for the upcoming release and the full year, with …
HUMA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -61.7%
Macy’s, Inc. Names Caitlin Howe Vice President, Investor Relations
Macy's, Inc. has appointed Caitlin Howe as its new Vice President, Investor Relations, effective July 20, 2026. Howe, previously Senior Vice President of Finance at The RealReal, brings extensive experience in investor relations, corporate finance, and M&A from the retail and e-commerce sectors. She …
M
main company
Sharemaestro market context
Trend signal active
52 weeks +78.9%
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) experienced a larger drop than the general market, closing down 1.28% against a backdrop of slight S&P 500 and Nasdaq depreciation, and a 0.59% Dow downswing. The company's stock has fallen 28.09% in the past month, underperforming the Medical sector and …
HUMA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -61.7%
Is Now The Time To Look At Buying Macy's, Inc. (NYSE:M)?
This article examines whether Macy's, Inc. (NYSE:M) stock presents a good buying opportunity. It likely delves into various financial metrics, market sentiment, and future prospects to assess the investment potential of the retail giant. The analysis will help investors decide if the current market …
M
main company
Sharemaestro market context
Trend signal active
52 weeks +78.9%
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN
This document is a Form 4 statement filed by PharmaCyte Biotech, detailing changes in beneficial ownership of securities for Director Jonathan Schechter. The filing indicates transactions related to his holdings within the company.
PMCB
main company
Sharemaestro market context
Price below Trend Line
52 weeks -43.2% · Next-week setup negative 43.2%
Guardian Pharmacy Services, Inc. to Report Second Quarter 2026 Financial Results and Host Conference Call
Guardian Pharmacy Services, Inc. (NYSE: GRDN) announced it will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss these results. The company, a leading long-term …
GRDN
main company
Sharemaestro market context
Trend signal active
52 weeks +49.0%
[Form 4/A] PharmaCyte Biotech, Inc. Amended Insider Trading Activity
PharmaCyte Biotech, Inc. Director Michael M. Abecassis filed an amended Form 4/A, which clarifies a previous insider transaction. The amendment states that an earlier reported grant of a stock option was made in error and has since been canceled, resulting in zero shares and …
PMCB
main company
Sharemaestro market context
Price below Trend Line
52 weeks -43.2% · Next-week setup negative 43.2%
PharmaCyte Biotech (PMCB) cancels erroneous stock option grant
PharmaCyte Biotech (PMCB) director Robert Weinstein has corrected a stock option award previously granted on March 31, 2026. The initial grant, reported as a Stock Option (Right to Buy), was made in error and has now been officially cancelled. This amendment to the Form …
PMCB
main company
Sharemaestro market context
Price below Trend Line
52 weeks -43.2% · Next-week setup negative 43.2%
PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant
PharmaCyte Biotech director Jonathan Schechter filed an amended insider report (Form 4/A) to cancel a previously reported stock option grant dated March 31, 2026. This amendment clarifies that the initial grant was made in error and has been subsequently cancelled, resulting in zero outstanding …
PMCB
main company
Sharemaestro market context
Price below Trend Line
52 weeks -43.2% · Next-week setup negative 43.2%
Starbucks to reopen at Staten Island Mall in October: Here’s a peek at the new layout
A licensed Starbucks cafe is set to reopen at the Staten Island Mall in New Springville, New York, in October. Located inside Macy's women's department on the upper level, this new shop-within-a-shop replaces the previous Starbucks that closed in December. The cafe will be …
M
main company
Sharemaestro market context
Trend signal active
52 weeks +78.9%
Wellness Concepts in Grottoes acquired by Guardian Pharmacy Services
Guardian Pharmacy Services has acquired Wellness Concepts, a long-term care pharmacy based in Grottoes, Virginia. The acquisition means Wellness Concepts will retain its current leadership and staff, including President Brent Atwell, a second-generation pharmacist. This move strengthens Guardian Pharmacy Services' presence in Virginia and …
GRDN
main company
Sharemaestro market context
Trend signal active
52 weeks +49.0%
Guardian Pharmacy to report Q2 2026 results on August 6
Guardian Pharmacy Services will announce its second quarter 2026 financial results after market close on August 6, 2026, followed by a conference call at 4:30 p.m. Eastern Time. The company, which operates 61 licensed pharmacies serving approximately 207,000 residents, will host the call for …
GRDN
main company
Sharemaestro market context
Trend signal active
52 weeks +49.0%
Macy’s Inc. Taps Alex Choueiri as CEO of Bluemercury
Macy's Inc. has appointed Alex Choueiri, a former Kering Beauté executive, as the new CEO of Bluemercury, effective August 3rd. Choueiri brings over 25 years of experience in luxury beauty, having worked at Kering Beauté Americas and L’Oréal. This strategic move aims to leverage …
M
main company
Sharemaestro market context
Trend signal active
52 weeks +78.9%
Macy’s Inc. taps Kering Beauté exec to lead Bluemercury
Macy’s Inc. has appointed Alexandre Choueiri, formerly of Kering Beauté, as the new CEO of Bluemercury, effective August 3. Choueiri brings over 25 years of experience in luxury beauty, having previously led Kering Beauté's Americas region and held various roles at L'Oréal. His appointment …
M
main company
Sharemaestro market context
Trend signal active
52 weeks +78.9%